ImmunoCAP 1000 System Analyzers with Service and Maintenance
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Defense Health Agency (DHA) intends to award a sole source contract to Phadia US, Inc. for ImmunoCAP 1000 System Analyzers with Service and Maintenance at Wilford Hall Ambulatory Surgical Center (WHASC), Joint Base San Antonio, Texas. This Special Notice seeks to identify other responsible sources capable of providing these reagents, consumables, and services. Responses are due March 20, 2026.
Scope of Requirement
The requirement is for reagents and consumables for two ImmunoCAP 1000 System Analyzers, including associated service and maintenance. The notice lists specific quantities for various reagent codes (e.g., 41AD - Qty - 180, 41AE - Qty - 6, 53GX - Qty - 800, etc.) and two 1000 Immunoassay System Analyzers. The agency will consider alternate products if full descriptions and salient characteristics are provided.
Contract Details
- Opportunity Type: Special Notice / Notice of Intent to Sole Source
- Authority: FAR Part 6.103-1 (Only one responsible source)
- NAICS: 334516, Analytical Laboratory Instrument Manufacturing (Size Standard: 1,000 employees)
- PSC: 6550, In Vitro Diagnostic Substances, Reagents, Test Kits and Sets
- Place of Performance: Wilford Hall Ambulatory Surgical Center (WHASC), Joint Base San Antonio, Texas
- Intended Awardee: Phadia US, Inc. (Cage Code: 1QNW5)
Response Requirements & Timeline
This is not a request for competitive quotes. Interested parties who believe they can meet the requirement must submit the following:
- Business name, type, and socio-economic status
- Point of contact (name, phone, email)
- GSA Contract number (if applicable)
- SAM Unique Entity ID
- A capability statement narrative (not to exceed 1 page) demonstrating the ability to provide the specified reagents, consumables, and services for the ImmunoCAP 1000 System Analyzers.
Responses are due no later than 4:00 P.M. CT on March 20, 2026. Submissions should be emailed to Mr. Joe Wells at joe.d.wells3.civ@health.mil. The Government will use responses to determine whether to proceed with a sole source award or issue a competitive solicitation.